Halda Therapeutics Raises $126M to Progress RIPTAC™ Cancer Treatments for Key Solid Tumors into Clinical Trials.

The FDA has given the green light to YORVIPATH® (Palopegteriparatide), marking it as the inaugural treatment option for adult hypoparathyroidism.

IASO Bio Gains U.S. FDA Clearance for Investigational New Drug Application of Equecabtagene Autoleucel for Two Additional Autoimmune Disorders.

Merck, via one of its subsidiaries, will acquire CN201, an innovative investigational bispecific antibody currently in the clinical trial phase for treating B-cell related disorders.

TG Therapeutics, has obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application to study Azercabtagene Zapreleucel (azer-cel).

Angiex, has commenced patient dosing in their Phase 1 clinical trial of AGX101, an innovative TM4SF1-targeted Antibody-Drug Conjugate (ADC).

ARS Pharmaceuticals has recently achieved a milestone with the U.S. Food and Drug Administration (FDA) approval of neffy® (epinephrine nasal spray) 2 mg.

Merck Shares Update on Phase 3 Trial KeyVibe-008 Testing Vibostolimab and Pembrolizumab Combo in Extensive-Stage Small Cell Lung Cancer.

Novartis gets FDA fast-track approval for Fabhalta® (iptacopan), marking it as the inaugural complement inhibitor to lower proteinuria in primary IgA nephropathy (IgAN).

Invenra Showcases Exelixis’ News: Phase 1 Clinical Trial Begins for XB010 in Advanced Solid Tumor Patients.

This study is assessing the safety and tolerability of MTX-474, a human IgG1 antibody created to inhibit EphrinB2 signaling.

Takeda Gains European Commission Clearance for ADZYNMA (Recombinant ADAMTS13), the First Recombinant ADAMTS13 Therapy for cTTP.